Sabby Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Sabby Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16,909	Closed	-$327K	–	149
2018 Q3	$327K	Sell	16,909 -1,404	-8%	-$25.5K	0.04%	84
2018 Q2	$331K	Buy	+18,313	New	+$270K	0.05%	93
2018 Q1	–	Sell	-14,433	Closed	-$608K	–	196
2017 Q4	$608K	Sell	14,433 -65,887	-82%	-$2.96M	0.06%	98
2017 Q3	$4.42M	Buy	+80,320	New	+$13.5M	0.29%	42
2017 Q2	–	Sell	-2,089	Closed	-$366K	–	273
2017 Q1	$250K	Sell	2,089 -10,536	-83%	-$1.1M	0.01%	208
2016 Q4	$1.25M	Buy	12,625 +986	+8%	+$104K	0.07%	134
2016 Q3	$1.3M	Sell	11,639 -12,111	-51%	-$1.45M	0.05%	162
2016 Q2	$2.44M	Buy	23,750 +19,495	+458%	+$1.95M	0.13%	94
2016 Q1	$391K	Buy	+4,255	New	+$454K	0.02%	231
2015 Q4	–	Sell	-2,632	Closed	-$272K	–	386
2015 Q3	$272K	Buy	+2,632	New	+$309K	0.01%	331

Other funds holding SIOX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sabby Management's SIOX Position: Q4 2018 in Review

Sabby Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 16,909 shares — an estimated $327K sold.

Sabby Management first reported a position in SIOX in Q3 2015 and held it in 10 quarters. The position peaked at $4.42M in Q3 2017. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

Sabby Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Sabby Management sold 16,909 Sio Gene Therapies Inc. Common Stock shares in Q4 2018, an estimated $327K.
Sabby Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 10 quarters.
Sabby Management's Sio Gene Therapies Inc. Common Stock position peaked at $4.42M in Q3 2017.
61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.